CA-AERA-TECHNOLOGY
7.11.2022 18:31:39 CET | Business Wire | Press release
Aera Technology, the Decision Intelligence company, today announced it has been named a 2022 CNBC Top Startup for the Enterprise.
Since its inception in 2017, Aera has played a key role in defining the Decision Intelligence market category by proving the scalability of its patented Aera Decision Cloud™ platform among large global enterprises with complex operations and supply chains. Today, Aera Decision Cloud is integral to the technology stacks of several of the largest worldwide companies across consumer packaged goods, healthcare and life sciences, manufacturing, and more.
“Today’s recognition by CNBC is validation of our work helping enterprises re-imagine decision making through a purpose-built platform for Decision Intelligence,” said Fred Laluyaux, CEO, Aera Technology. “Using Aera Decision Cloud, our customers are connecting the dots across business functions to automate and execute fast, accurate decisions at the right moment in time.”
The patented Aera Decision Cloud provides the advanced technologies and tools required to aggregate and integrate data from internal and external systems and build and deploy decision-making models that generate recommendations for any business scenario. Enterprises can support, augment, or automate their decision-making processes with the ability to retain a permanent memory of the decisions executed — fueling institutional knowledge for current and future teams, and continually improving performance and metrics.
The inaugural 2022 CNBC Top Startup for the Enterprise list identifies the 25 fast-growth startups with the potential to drive value and investment interest for the enterprise. The list is based on a proprietary analysis of quantitative metrics and qualitative review by the members of CNBC’s Technology Executive Council (TEC), which is comprised of leading CTOs, CIOs, CISOs and others in technology functions. For more information, visit cnbc.com/tec.
Aera Technology
Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bracco Expands BubbleGen Cell Selection with CD3+ T Cell Isolation Kit9.9.2026 14:00:00 CEST | Press release
Microbubble-based technology enables magnetic bead-free cell selection for cell therapy research and development Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, today announced the expansion of its BubbleGen™ cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on Bracco's microbubble technology, can enable new cell therapy workflows, including a highly scalable and cost-effective approach to manufacturing CAR-T cell therapies. This marks the first of multiple planned expansions of the BubbleGen family of cell selection solutions following the launch of its early access program in May this year. Cell selection is a critical step in cell therapy manufacturing, but the industry standard magnetic bead-based approach adds complexity, time, and cost to workflows – the enemies of scale. BubbleGen is Bracco’s response to industry demand for non-magnetic bead-based alternati
New Visa Research Finds Consumer Trust is Accelerating the Path to Agentic Commerce9.9.2026 13:00:00 CEST | Press release
Consumers rank Visa as the most trusted brand to deliver AI-powered commerce. Visa (NYSE: V) today announced the Visa Trust Index for agentic commerce, providing new insight into how consumers are navigating the next evolution of AI shopping and payments. While consumers are increasingly using AI across the shopping journey, only 23% of U.S. consumers trust GenAI to handle payment transactions on their behalf. However, confidence in agentic commerce shifts when payments brands come into consideration. Visa emerged as the most trusted brand for AI-powered payments with 61% of respondents saying they would trust Visa to handle agentic transactions. The findings suggest that while consumers are intrigued by agentic commerce, trust remains the key factor determining whether adoption moves from possibility to reality. "AI has the potential to fundamentally reshape how people discover, buy and pay for goods and services, much like e-commerce and mobile commerce did before it," said Oliver Je
NIQ’s Optiq™ Goes Live in Discover, Expanding Access to Trusted Consumer Intelligence9.9.2026 12:45:00 CEST | Press release
Global beta rollout of NIQ’s Optiq Chat later this month will give more clients conversational access to explainable answers grounded in NIQ data and expertise NielsenIQ (NIQ), a leading consumer intelligence company, today announced that Optiq is now live within Discover, NIQ’s platform for accessing, analyzing and applying consumer and market intelligence, advancing the company’s strategy to make trusted consumer intelligence easier to access and apply. Where Ask Arthur introduced new ways to explore and analyze NIQ data through AI within Discover, Optiq expands that experience across conversational AI, mobile access and enterprise AI integrations, giving clients greater flexibility to access and apply NIQ intelligence across the applications and workflows where they make decisions. “AI models are becoming ubiquitous. Trusted intelligence is not,” said Irina Stoian, Chief AI Commercial Officer at NIQ. “That is why we are building the full system. Think of it like a body: harmonized N
Cegid and Silae Join Forces to Create a European Leader in AI-Driven Business Technology9.9.2026 12:32:00 CEST | Press release
Planned Merger Enables Trusted, Fully Integrated Experience Across E-Invoicing, Accounting, Tax, Payroll and HR, Digital Financial Services and Payments for Businesses and their PartnersChristian Pedersen Joins Cegid as CEO to Lead Combined Group Cegid, an AI-driven European leader in cloud business management software for small and medium-sized businesses (SMBs), and accounting professionals, and Silae, France’s leading payroll and human resources platform, today announced their intention to merge. The combination will create a national technology champion and the leading European technology platform for businesses and their partners, helping them grow safely and efficiently with the support of a fully integrated and compliant suite covering their end-to-end financial and administrative needs. Between them, Cegid, following its recent acquisition of Shine, and Silae power the day-to-day accounting, tax, finance and payroll of 2 million end-customers and more than 15,000 chartered acco
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year9.9.2026 12:30:00 CEST | Press release
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized to the 25 mg arm and received an additional doseFor participants randomized to Placebo arm who received first dose of COMP360 25 mg in open-label Part C, data further reinforces that a single 25 mg dose can produce rapid onset, meaningful effect and durabilityFor all participants in Part C who received a 25 mg open-label dose, strong response and remission rates were observed with 40%-45% responders2 and approximately 30% remitters3 across all timepoints 6 weeks post the Part C doseThis 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a yearCOMP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom